CareDx, Inc., a transplant diagnostics company, together with its subsidiaries, engages in the discovery, development, and commercialization of diagnostic surveillance solutions for transplant patients worldwide. It operates through two segments, Post-Transplant Diagnostics and Pre-Transplant Diagnostics. The Post-Transplant Diagnostics segment develops and provides a diagnostic surveillance testing solution for heart and kidney transplant recipients. It offers AlloMap, a heart transplant molecular test; and AlloSure, a donor-derived cell free DNA test initially used for kidney transplant patients. The Pre-Transplant Diagnostics segment develops, manufactures, markets, and sells products that increase the chance of successful transplants by facilitating a match between a donor and a recipient of stem cells and organs. It sells Olerup SSP, which is used to type human leukocyte antigen (HAL) alleles based on sequence-specific primer technology; Olerup QTYPE, a test kit for sequence based HLA typing; Olerup SBT, a test kit for sequence based HLA typing; and XM-ONE, a test that identifies a patient's antigens against HLA Class I or Class II, as well as antibodies against a donor's endothelium. This segment offers its products directly to customers, as well as through third-party distributors. The company was formerly known as XDx, Inc. and changed its name to CareDx, Inc. in March 2014. CareDx, Inc. was incorporated in 1998 and is headquartered in Brisbane, California.
Industry, Sector and Symbol
Industry Medical laboratories
Sub-IndustryN/A
SectorMedical
SymbolNASDAQ:CDNA
CUSIPN/A
Phone415-287-2300
Debt
Debt-to-Equity Ratio0.29
Current Ratio2.43
Quick Ratio2.06
Price-To-Earnings
Trailing P/E Ratio-18.97
Forward P/E Ratio-29.82
P/E GrowthN/A
Sales & Book Value
Annual Sales$48.32 million
Price / Sales10.67
Cash FlowN/A
Price / CashN/A
Book Value($0.21) per share
Price / Book-69.57
Profitability
EPS (Most Recent Fiscal Year)($0.77)
Net Income$-55,460,000.00
Net Margins-115.91%
Return on Equity-158.93%
Return on Assets-19.78%
Miscellaneous
Employees179
Outstanding Shares35,280,000
CareDx (NASDAQ:CDNA) Frequently Asked Questions
What is CareDx's stock symbol?
CareDx trades on the NASDAQ under the ticker symbol "CDNA."
How were CareDx's earnings last quarter?
CareDx Inc (NASDAQ:CDNA) announced its earnings results on Thursday, May, 10th. The company reported ($0.14) EPS for the quarter, missing the Thomson Reuters' consensus estimate of ($0.13) by $0.01. The business had revenue of $14.05 million for the quarter, compared to the consensus estimate of $13.91 million. CareDx had a negative return on equity of 158.93% and a negative net margin of 115.91%. View CareDx's Earnings History.
What price target have analysts set for CDNA?
4 brokers have issued 1 year price targets for CareDx's stock. Their predictions range from $6.50 to $17.00. On average, they expect CareDx's share price to reach $12.1250 in the next year. View Analyst Ratings for CareDx.
What are Wall Street analysts saying about CareDx stock?
Here are some recent quotes from research analysts about CareDx stock:
- 1. HC Wainwright analysts commented, "We currently estimate that over 5,700 and 15,000 AlloSure tests could be performed in 2018 and 2019, respectively. Our current estimated enterprise value of the firm is $545M, up from $510M. Excluding $15M debt and assuming 35.5M shares outstanding at the end of 2Q19, this translates to a per share value of approximately $15. Therefore, we have raised our 12-month price target to $15 from $14 per share. Considering CDNA shares are currently trading slightly above $15 a share, we are downgrading our rating to Neutral from Buy." (6/19/2018)
- 2. According to Zacks Investment Research, "CareDx, Inc. is a commercial stage company. It develops, markets, and delivers a diagnostic surveillance solution for heart transplant recipients. The Company provides AlloMap, a noninvasive blood test used to aid in the identification of heart transplant recipients. It is also pursuing other areas of transplant surveillance, such as the use of cell-free DNA (cfDNA) as a biomarker for rejection. CareDx, Inc. is based in Brisbane, California. " (1/11/2018)
Who are some of CareDx's key competitors?
Some companies that are related to CareDx include Genomic Health (GHDX), Natera (NTRA), RadNet (RDNT), InVitae (NVTA), Veracyte (VCYT), Enzo Biochem (ENZ), Miragen Therapeutics (MGEN), PotNetwork (POTN), Celcuity (CELC), Psychemedics (PMD), Fulgent Genetics (FLGT), First Choice Healthcare Solutions (FCHS), Cancer Genetics (CGIX), Biocept (BIOC) and OpGen (OPGN).
Who are CareDx's key executives?
CareDx's management team includes the folowing people:
- Dr. Peter Maag, Pres, CEO & Director (Age 51)
- Mr. Michael Bell, Chief Financial Officer (Age 49)
- Dr. James P. Yee, Chief Medical Officer (Age 69)
- Dr. Mitchell J. Nelles, Chief Operating Officer (Age 65)
- Dr. John J. Sninsky Ph.D., Chief Scientific Officer (Age 68)
Has CareDx been receiving favorable news coverage?
Press coverage about CDNA stock has trended somewhat positive on Thursday, according to Accern. Accern ranks the sentiment of press coverage by monitoring more than twenty million blog and news sources in real-time. Accern ranks coverage of companies on a scale of -1 to 1, with scores closest to one being the most favorable. CareDx earned a daily sentiment score of 0.19 on Accern's scale. They also assigned press coverage about the company an impact score of 46.86 out of 100, indicating that recent press coverage is somewhat unlikely to have an effect on the company's share price in the near term.
Who are CareDx's major shareholders?
CareDx's stock is owned by a number of of retail and institutional investors. Top institutional shareholders include ALGER ASSOCIATES INC (10.49%), Gagnon Securities LLC (5.08%), MIDROC INVEST AB (4.50%), Next Century Growth Investors LLC (4.47%), Polar Asset Management Partners Inc. (2.44%) and Park West Asset Management LLC (1.41%). Company insiders that own CareDx stock include James P Yee, Michael Brian Bell, Mitchell J Nelles, Neil Gagnon and Peter Maag. View Institutional Ownership Trends for CareDx.
Which major investors are selling CareDx stock?
CDNA stock was sold by a variety of institutional investors in the last quarter, including Park West Asset Management LLC, Thompson Davis & CO. Inc. and Gagnon Securities LLC. Company insiders that have sold CareDx company stock in the last year include James P Yee, Mitchell J Nelles and Peter Maag. View Insider Buying and Selling for CareDx.
Which major investors are buying CareDx stock?
CDNA stock was purchased by a variety of institutional investors in the last quarter, including Polar Asset Management Partners Inc., Next Century Growth Investors LLC, Millrace Asset Group Inc., Millennium Management LLC, Spark Investment Management LLC, Trexquant Investment LP, Tibra Equities Europe Ltd and Clear Harbor Asset Management LLC. Company insiders that have bought CareDx stock in the last two years include Michael Brian Bell, Neil Gagnon and Peter Maag. View Insider Buying and Selling for CareDx.
How do I buy shares of CareDx?
Shares of CDNA can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.
What is CareDx's stock price today?
One share of CDNA stock can currently be purchased for approximately $14.61.
How big of a company is CareDx?
CareDx has a market capitalization of $550.42 million and generates $48.32 million in revenue each year. The company earns $-55,460,000.00 in net income (profit) each year or ($0.77) on an earnings per share basis. CareDx employs 179 workers across the globe.
How can I contact CareDx?
CareDx's mailing address is 3260 BAYSHORE BOULEVARD, BRISBANE CA, 94005. The company can be reached via phone at 415-287-2300 or via email at [email protected]
MarketBeat Community Rating for CareDx (CDNA)
MarketBeat's community ratings are surveys of what our community members think about CareDx and other stocks. Vote "Outperform" if you believe CDNA will outperform the S&P 500 over the long term. Vote "Underperform" if you believe CDNA will underperform the S&P 500 over the long term. You may vote once every thirty days.
